产品介绍：
产品说明
包装
5, 25 mg in glass bottle
生化/生理作用
LY320135 is a potent CB1 receptor antagonist/inverse agonist (Ki = 141 nM) with greater than 70-fold selectivity over CB2 receptors (Ki > 10 μM). Structurally dissimilar from SR 141716A and AM 251. Shows weak binding to both 5-HT2 (Ki = 6.4 μM) and muscarinic receptors (Ki = 2.1 μM)
特点和优势
This compound is featured on the Cannabinoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
基本信息
| 经验(实验)分子式 | C24H17NO4 |
| 分子量 | 383.40 |
| MDL编号 | MFCD00945878 |
| PubChem化学物质编号 | 329817622 |
| NACRES | NA.77 |
产品性质
| 质量水平 | 100 |
| 测定 | ≥98% (HPLC) |
| 形式 | powder |
| 颜色 | orange |
| 溶解性 | DMSO: ≥10 mg/mL |
| 创始人 | Eli Lilly |
| 储存温度 | 2-8℃ |
| SMILES string | COc1ccc(cc1)-c2oc3cc(OC)ccc3c2C(=O)c4ccc(cc4)C#N |
| InChI | 1S/C24H17NO4/c1-27-18-9-7-17(8-10-18)24-22(20-12-11-19(28-2)13-21(20)29-24)23(26)16-5-3-15(14-25)4-6-16/h3-13H,1-2H3 |
| InChI key | RYNSGDFWBJWWSZ-UHFFFAOYSA-N |
安全信息
| 象形图 |  |
| 警示用语： | Danger |
| 危险声明 | H301 |
| 预防措施声明 | P301 + P310 |
| 危险分类 | Acute Tox. 3 Oral |
| 储存分类代码 | 6.1D - Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects |
| WGK | WGK 3 |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |
